SUBSCRIBE
SUBSCRIBE
Dan Samorodnitsky

Dan Samorodnitsky

News Editor

Dan Samorodnitsky is the news editor at BioSpace. He has a decade of experience covering biotech, genetics and medicine. Before coming to BioSpace he was an editor at Drug Discovery News and Massive Science, and his writing has appeared in outlets such as Quanta, STAT, GROW and many others. He is based in Minneapolis. You can reach him at dan.samorodnitsky@biospace.com.

Johnson and Johnson sign
Earnings
J&J Aims for $100B in Sales, Puts Stelara Patent Cliff ‘in the Rearview Mirror’
Reporting Q4 and full year earnings on Wednesday, J&J executives hailed growth across the healthcare giant’s portfolio while standing fast on its talc lawsuit and tariffs.
January 21, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Industry Leader and Market Dominance of a Company
Business
JPM26: KalVista’s HAE Win Is a ‘Tale of Two Markets’
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
January 21, 2026
 · 
3 min read
 · 
Dan Samorodnitsky
Podcast
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
The obesity market and Most Favored Nation drug pricing were among the topics de jour at the J.P. Morgan Healthcare Conference last week, while smaller biotechs sought to assure investors that their regulatory ducks are in a row; Novo Nordisk’s oral obesity pill got off to a hot start while the FDA delayed a decision on Eli Lilly’s investigational offering; and SpyGlass Pharma and AgomAb Therapeutics join the 2026 IPO club.
January 21, 2026
 · 
1 min read
 · 
Heather McKenzie
Vector artwork depicts underdog wins.
Obesity
JPM26: After a Tough 2025, Biohaven Is Gearing Up To Challenge Goliath—Lilly
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
January 20, 2026
 · 
3 min read
 · 
Dan Samorodnitsky
Top view of successful businessman lost in labyrinth
RNA editing
JPM26: Korro Bio Looks To Save Itself Despite Unenviable Position
After a cacophony of troubles hit the RNA editing biotech last fall, CEO Ram Aiyar is in San Francisco to develop partnerships, pitch the potential of its new AATD program and find more money to keep the dream alive.
January 16, 2026
 · 
3 min read
 · 
Dan Samorodnitsky
place marker transportation to the destination, Locating destinations and locations travel for business in large places,3d rendering
Editorial
JPM26: Verizon Outage Unites Directionless Conference Goers
It doesn’t matter how many times you have traversed Union Square; no one knows which way is north, or where The Westin is in relation to the Ritz Carlton. A Verizon outage brought that into focus on Wednesday.
January 15, 2026
 · 
1 min read
 · 
Annalee Armstrong
Nov 2, 2019 San Francisco / CA / USA - People visiting the Gilead exhibition at the Bay Area Science festival; free access, no ticket required
HIV
JPM26: Gilead Captures Sunny JPM Mood With Yeztugo Numbers, HIV Vibes
At a J.P. Morgan media event Tuesday, the Gilead C-suite seemed to be walking on air as they highlighted Yeztugo’s capture of the HIV market and its plans for business development.
January 14, 2026
 · 
3 min read
 · 
Dan Samorodnitsky
Podcast
Deals Roll at JPM26, Policy Front and Center, IPOs Are Back, FDA Stays Busy
AbbVie and Novartis strike billion-dollar pacts while attendees at the J.P. Morgan Healthcare Conference await that one big M&A deal and Merck teases limitless buying capacity; Eli Lilly readies for potential orforglipron launch while Novo Nordisk laments compounders; the IPO window cracks open; and the FDA concludes that GLP-1s do not pose a suicide risk.
January 14, 2026
 · 
2 min read
 · 
Heather McKenzie
abstract image of DNA, tablets and planet earth. 3D-image
Policy
At JPM26, Experts Try To Look Past the Most Favored Nation ‘Distraction’
Former European Trade Commissioner Phil Hogan and former US Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
January 12, 2026
 · 
4 min read
 · 
Dan Samorodnitsky
Creative picture image collage banner of guy worker jump from financial charts determined company success.
Earnings
Insmed Jumps on ‘Blowout’ Sales Beat for Bronchiectasis Drug Brinsupri
Insmed’s freshly approved lung condition drug soared past sales expectations for 2025, netting $144.6 million in its first full quarter of sales.
January 9, 2026
 · 
1 min read
 · 
Dan Samorodnitsky
Retro styled image of a set of different colorful alarm clocks
Complete response letters
Vanda Slides After FDA Again Rejects Hetlioz For Jet Lag
The DC-based biopharma disputed the FDA’s conclusions regarding the data provided in its supplemental application for Hetlioz and promised to keep pushing for an approval.
January 8, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Focus on the path, Businessman running on his own track
Rare diseases
Crinetics Advances Potential Neurocrine Competitor With Fresh Data and Money
The company announced a $350 million public offering on Monday shortly after revealing positive Phase II results for its investigational congenital adrenal hyperplasia drug, with hopes to one day compete with Neurocrine’s Crenessity.
January 7, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Podcast
Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus
Novo Nordisk follows Christmas oral Wegovy approval with quick launch; Eli Lilly is headed for $94.3 billion in annual revenue by 2027, analysts predict; nine more pharmas strike Most Favored Nation deals but half remain unsigned; experts call for stability and rare disease action at FDA, and all eyes are on M&A ahead of the J.P. Morgan Healthcare conference next week.
January 7, 2026
 · 
2 min read
 · 
Heather McKenzie
3D Illustration of unlucky business man under rain, surreal concept
Vaccines
Vaccine Investors Keep Their Heads Down as Trump Cuts Shot Schedule
The US dramatically altered its recommendations for a series of vaccines, which drive billion-dollar earnings for giants like Merck and Pfizer.
January 6, 2026
 · 
3 min read
 · 
Dan Samorodnitsky
Novo Nordisk's logo on the facade of its building in Germany
Obesity
Novo Unveils Oral Wegovy in the US, With Out-of-Pocket Prices at $149 Per Month
After getting the crucial first-mover advantage with an FDA approval for a weight loss pill, Novo Nordisk looks to win the market before rival Lilly can arrive with its own oral option for obesity.
January 5, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Load More